Immune Pharmaceuticals Valuation

Immune Pharmaceuticals seems to be undervalued based on Macroaxis valuation methodology. This module calculates value of Immune Pharmaceuticals from evaluating the corporation fundamentals such as Shares Owned by Institutions of 0.06%, Current Valuation of 8.67M and Return On Asset of (42.63)% as well as inspecting its technical indicators and Probability Of Bankruptcy. In general, we encourage to acquire undervalued assets and to sell overvalued assets since at some point stocks prices and their ongoing real values will come together.
Horizon     30 Days    Login   to change
Immune Pharmaceuticals is currently regarded as number one stock in price to sales category among related companies. It is currently regarded as number one stock in price to earning category among related companies .
Follow Benchmarks with Macroaxis syndicated feed, custom widget, or your favorite custom stock ticker
See also Risk vs Return Analysis. Please also try Aroon Oscillator module to analyze current equity momentum using aroon oscillator and other momentum ratios.
Search macroaxis.com